ENSC (Ensysce) רווחיות לפי רווח גולמי

The gross margin history of Ensysce Biosciences (ENSC) demonstrates current efficiency, where the parameter value equals 0.00. Risks are associated with stringent FDA oversight and capital shortages leading to share dilution. Business protection is based on unique MPAR patents that block competitor entry. Revenues rely on demand from insurance companies and patients with chronic pain within the safe opioid segment.
פילוחי מדדים פיננסיים ומדדי שוק עבור Ensysce Biosciences (ENSC)

Ensysce Biosciences (ENSC) is developing the specialized TAAP system to combat the opioid crisis, leveraging regulatory grants and technological uniqueness. By analyzing the gross profit margin on GURU.Markets, an investor can identify the portion of revenue remaining after direct production costs. This indicator measures the business's internal margin of safety, allowing for an assessment of the company's real operational efficiency before accounting for administrative expenses.